Cancer News

Medindia's Press Release’ section provides the latest press release on Cancer from across the world for the global audience. This page links to 7624 Cancer press releases.

Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers

PR Newswire PHILADELPHIA, Nov. 15, 2024 PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of ...


Researchers uncover new role of mutant proteins in some of the deadliest cancers

PR Newswire BETHESDA, Md., Nov. 12, 2024 Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have ...

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

PR Newswire SHANGHAI, Nov. 11, 2024 – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2%  for placebo (p SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- Abbisko today announced ...

Triumvira Immunologics' Late-Breaking Abstract Selected for Oral Presentation at the 39th SITC Annual Meeting Demonstrates Preliminary Safety and Promising Clinical Activity of TAC01-CLDN18.2 Cell Therapy in Patients with Solid Tumors

PR Newswire HOUSTON and SAN DIEGO, Nov. 11, 2024 TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial A pancreatic cancer patient treated with ...

Optic AI and Vindur Tx Close $17.5m Deal to Accelerate Breakthroughs for Difficult-to-treat Cancers

PR Newswire SAN FRANCISCO, Nov. 11, 2024 SAN FRANCISCO, Nov. 11, 2024 /PRNewswire/ -- Optic, a digital biology company redefining drug discovery with AI, announced a collaboration with Vindur Tx, an early-stage oncology therapeutics venture. ...

Theragent and CellVax Therapeutics Announce First Patient Dosed in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

PR Newswire ARCADIA, Calif., Nov. 11, 2024 ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ -- Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both ...

STAND UP TO CANCER COLLABORATES WITH JOHNSON & JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS

PR Newswire LOS ANGELES, Nov. 11, 2024 LOS ANGELES, Nov. 11, 2024 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted ...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

PR Newswire CRANFORD, N.J., Nov. 11, 2024 Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% ...

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

PR Newswire SAN DIEGO, Nov. 11, 2024 Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors ...

Sapience Therapeutics Presents Clinical Data on Two Lead Programs, Including ST101 Oral Presentation, at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

PR Newswire TARRYTOWN, N.Y., Nov. 9, 2024 -ST101 Phase 2 data demonstrates activation of the tumor immune microenvironment in glioblastoma (GBM)- -ST316 Phase 1 data demonstrates antagonism of ß-catenin-driven immune exclusion- ...

Cancer News »

A New Understanding of Skin Cancer

A New Understanding of Skin Cancer

A new study reveals a key mechanism driving skin cancer. Researchers have identified a protein-ion channel interaction that fuels tumor growth. ( ) What is Melanoma Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin ...

Alcohol Increases Cancer Risk, Yet Few Know It

Alcohol Increases Cancer Risk, Yet Few Know It

While the Centers for Disease Control and Prevention (CDC) advises that reducing alcohol consumption or abstaining can lower cancer risk, data from the Annenberg Public Policy Center (APPC) reveal that fewer than half of Americans are aware that regular alcohol consumption increases the risk of developing cancer later in life. ...

Copper Removal: A New Approach to Kill Cancer Cells

Copper Removal: A New Approach to Kill Cancer Cells

Copper is a micronutrient that is essential for the body to perform biological functions. While copper is required for enzymatic activities, tumor cells require more copper than healthy cells for its growth. A new study from the Max Planck ...

Oral Immunotherapy: Yeast Probiotic Shrinks Gastrointestinal Tumors in Mice

Oral Immunotherapy: Yeast Probiotic Shrinks Gastrointestinal Tumors in Mice

Immunotherapy is a promising treatment that harnesses the immune system to combat cancer, but its effectiveness has been limited in treating gastrointestinal cancers. ...

Triple Therapy Approach Yields Major Survival Gains in Unresectable Esophageal Cancer

Triple Therapy Approach Yields Major Survival Gains in Unresectable Esophageal Cancer

Adding immunotherapy to neoadjuvant chemoradiation can improve survival and enable surgery in esophageal cancer, reveals research results published in a journal of the American Association for Cancer Research. Bottom Line In patients with unresectable, locally advanced esophageal cancer, the combination of radiation, chemotherapy, and immunotherapy increased the likelihood of tumors becoming surgically removable, leading to significantly better ...

More Cancer News

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.